MM NM Flashcards
Bone marrow location
Skull
Clavicle
Sternum
Humerus
Pelvis
Femur
Vertebrae
Associated disease
Myelofibrosis
MM mechanism
Activate osteoclasts
Inhibit osteoblast
Bone resorption
Hypercalcemia
Presentation
Bone pain
Pathologic fracture
Beta2 microglobulin
M-protein IgG>IgA - - increase viscosity in eye and CNS - - visual impairment, hearing loss, dizziness
LDH
Spinal cord compression - - collapse of vertebral body in response to therapy
Immunodeficiency
MGUS
<10% plasma cells
Serum M-protein <3 g/dL
Normal bone on X-ray
Smoldering MM (stage IA)
> 10% plasma cells
Serum M-protein >3 g/dL or urine M-protein >1 g/dL
Single plasmacytoma
End organ damage CRAB
Calcium elevation
Renal insufficiency
Anemia
Bone abnormalities
MM characteristics
> 10% plasma cells or plasmacytoma
End organ damage
MM stage I lab
Hb >10 g/dL
Calcium <12 mg/dL
IgG <5 g/dL
IgA <3 g/dL
Urine M-protein < 4 g/24 h
MM stage IB
< 5 focal lesions >5 mm
On T1 MRI: micronodular or salt and pepper
MM stage III lab
Hb <8.5 g/dL
Calcium >12 mg/dL
IgG >7 g/dL
IgA >5 g/dL
Urine M-protein >12 g/24 h
MM stage II
5-20 focal lesions
On T1 MRI : contrast between vertebral bone marrow and disc
MM stage III
> 20 focal lesions
On T1 MRI : T1 signal less than disc
MM stage A
Creatinine <2 mg/dL
No extramedullary disease
MM stage B
Creatinine >2 mg/dL
Extramedullary disease
MGUS = monoclonal gammopathy of undetermined significance
Progression
Progression to MM 1% per year or Waldenstrom macroglobulinemia
Can progress to Primary Amyloidosis, CLL, lymphoma
MGBS
Macroglobulinemia of borderline significance
Higher risk of progression
10-30% plasma cells
SMM = smoldering MM
Asymptomatic (no end organ damage)
Higher risk of progression to MM
MM overview
Symptomatic
CRAB
Non-secretory - - no elevated M-protein
Micromolecular - - only light chains secreted
IgD MM
POEMS sy 1%
Polyneuropathy - symmetric, distal
Organomegaly
Endocrinopathy
M-protein
Skin changes + sclerotic bone lesions
Plasma cell leukemia
> 20% plasma cells
PCLI
Plasma cell labeling index
Correlated with neoangiogenesis
MGUS and SMM - - <1% PCLI
40% MM normal PCLI
Solitary plasmacytoma image
MRI, PET, DMSA
RAS = Radiographic skeletal survey
Punched - out Lytic lesions
Osteopenia
Fracture
MRI, PET
Bone scan insensitive
CT more sensitive - - >5 mm
Bone scan positive
Osteoblastic response to compression fracture or pelvic fracture
Soft tissue calcification
Tumor associated Amyloidosis
Ga67- citrate
Areas of active tumor
Low resolution
Multi day
Tc-DMSA
Accumulate in plasmacytoma
Tc-Sestamibi
Semiquantitative degree of bone marrow infiltration
Always negative in MGUS
False negative due to overexpression of P-glycoprotein (ass with multidrug resistant MM)
<MRI in spine
Replace Tl-Chloride
FDG indication
Initial staging
Early bone marrow infiltration (false positive young and anemia)
Extramedullary involvement (poor prognosis)
Negative in MGUS, MM stage I
Active transformed plasma cells
Glucose avid
Focal or diffuse uptake
Lesions <10mm
Not detected on FDG
FDG after surgery
At least 4 weeks
FDG after radio
2-3 months
Impetus = interpretative criteria for FDG in MM
Metabolic state of bone marrow
Number and site of positive lesions
Extramedullary disease
Paramedullary disease
Fractures
Choline
Higher sensitivity than FDG
High physiological liver uptake
C-Methionine
Incorporate into Ig
New Lytic lesions positive, recurring - negative
FLT
High uptake in myelodysplasia
Lower-absent uptake in MM, myelofibrosis, aplastic anemia
MGUS treatment
Long term observation
Solitary plasmacytoma treatment
Radio
MM treatment
Systemic therapy
Effective response
FDG rapidly declines
Persistent positive FDG
Early recurrence
M-protein
IgG 52 %
IgA 21 %
At diagnosis
10% diffuse osteopenia
Plasmacytoma
Solid lesion + soft tissue outside of bone or from preexistent bone lesion
No systemic spread
Minimum criteria for MM
At least 10% plasma cells
Or M-protein >3 g/dL in serum or >1g excreted in 24h urine
Poor prognosis
Translocation
Chromosomal alteration
Elevated PCLI
High risk SMM
Should be treated
80% CRAB in a short period
FDG focal uptake in MGUS
Transformation into active myeloma
> 10 spine lesions on MRI
6-11 fold risk of fracture
Radionuclide therapy
Anti CD45, CD66, CD138
CXCR4
Epidemiology
Number 1 primary tumor of bone
MRI detect
Iron overload
Amyloid
Marrow hyperplasia
Low sensitivity MRI
Sternum and ribs
PET better